期刊文献+

GC法测定利鲁唑含量 被引量:1

Determination of Riluzole by GC
下载PDF
导出
摘要 目的建立GC法测定利鲁唑原料的含量的方法。方法采用气相色谱内标法。色谱柱为DB-1弹性毛细管柱,FID检测器;汽化室温度为260℃,检测器温度为260℃;柱温为230℃,载气为高纯氮气,流速为5.0mL·min-1,尾吹30mL·min-1,分流比5∶1,以咖啡因为内标物。结果利鲁唑在10~110μg.mL-1(r=0.9998)范围内呈良好线性关系,平均回收率为100.1%(RSD=0.36%)。结论本方法简便,快速,准确,可靠,可用于利鲁唑的含量测定。 Objective GC method for determination of riluzole was established.Methods The internal standard GC method was applied.The chromatographic system was consisted of DB-1 capillary column and FID as detector.The injector temperature was 260℃.Tthe detector temperature was 260℃.Oven temperature was 230℃.The flow rate of N2 was 5.0mL·min-1.Makeup flow was 30mL·min-1.Split ratio was 5∶1.Caffeine was used as internal standard.Results A good linearity of riluzole was obtained between 10~110μg·mL-1(r=0.9998). The average recovery was 100.1% (RSD=0.36%). Conclusions The method is simple, rapid and accurate, and can be used in quality control of riluzole.
出处 《中国药事》 CAS 2009年第10期1007-1008,1014,共3页 Chinese Pharmaceutical Affairs
关键词 GC 利鲁唑 含量测定 内标法 GC riluzole determination internal standard method
  • 相关文献

参考文献15

二级参考文献44

  • 1[3]Le Liboux A, Lefebvre P, Le Roux Y, Truffinet P, Aubeneau M, Kesseli S, et al. Single-and multiple-dose pharmacokinetics of riluzole in white subjects[J]. J Clin Pharmacol, 1997; 37(9): 820-7
  • 2[4]Le liboux A, Paul C J, Kirkesseli S, Yves G J, Guimart C,Montay G, et al. A comparison of the pharmacokinetics and tolerability of riluzoe after repeat dose administration in healthy elderly and young volunteers[J] . J Clin Pharmacol, 1999; 39(5) :480 - 6
  • 3Wagner ML, Landis BE Riluzole:a new agent for amyotrophic lateral sclerosis[J].Ann Pharmacother, 1997, 31(6):738.
  • 4Le Liboux A, Cachia JP, Kirkesseli S, et al.A comparison of the pharmacokinetics and tolerability of riluzole after repeat dose administration in healthy elderly and young volunteers[J].J Clin Pharmacol, 1999, 39(5):480.
  • 5Bruno R, Vivier N, Montay G, et al.Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis[J].Clin Pharmacol Ther, 1997, 62(5):518.
  • 6Le Liboux A, Lefebvre P, Le Roux Y, et al.Single- and multiple- dose pharmacokinetics of riluzole in white subjects[J].J Clin Pharmacol, 1997, 37(9):820.
  • 7Dunlop J,Beal McIlvain H,She Y, et al. Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis[J]. J Neurosci, 2003,23(5):1688-1696.
  • 8Royberg H,Askmark H,Persson LI. A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate,aspartate,branched-chain amino acid levels and clinical parameters[J]. Acta Neurol Scand, 2003,108(1):1-8
  • 9Brooks BR. E1 Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis[J]. J Neurol Sci, 1994,124(suppl):96-107.
  • 10Couratier PH,Hugon J,Sindou P,et al. Cell culture evidence for neuronal degeneration in amyotrophic lateral sclerosis being linked to AMPA/kainate receptors[J]. Lancet, 1993,341:264-268.

共引文献46

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部